Despite barriers of blood, brain and bureaucracy, intranasal insulin may emerge as a promising treatment for pathological memory loss
The newest chemical under investigation for managing Alzheimer’s disease (AD) is actually not new at all. Insulin, the therapeutic hormone all-too familiar to individuals with diabetes, has been around for decades. In fact December will mark 90 years since its discoverers earned the Nobel Prize in Physiology or Medicine for the extraction of insulin for clinical use. Yet to say that insulin has been under our noses all these years wouldn’t exactly be correct. Because if it had been under our noses, we might have sensed its neurologic benefits sooner.
The latest insulin therapy is not delivered via injection like its diabetes-treating counterparts, nor does it come in the form of a pill or a patch like the cholinesterase inhibitors often prescribed to patients with AD. Instead this novel therapeutic enters the body through the nose—the only entry point that gives insulin a chance of reaching the brain.
A large peptide molecule, insulin from the blood cannot float easily into the brain because the blood brain barrier (BBB), a sort of neuroprotective moat, prevents its transport. Fortified by cellular guards called tight junctions, the BBB rejects many pharmacologic hopefuls, allowing entrance only to certain types of substances. Namely small or lipophilic molecules can be administered orally (or via injection, or through the skin) and as long as the relevant chemicals end up in the blood stream, they can casually saunter across the BBB and act on the brain. Large and cumbersome, insulin does not have this luxury and must therefore take a more creative route across the moat.
The nose, conspicuous and sometimes even goofy, provides that creative route. Yet it’s a route that, for many years, researchers were hesitant to take.
“They would say things like, ‘Well, why would there be a blood brain barrier if all you had to do was put something in the nose and it would go to the brain?’” says William H. Frey II, Ph.D., Research Director at HealthPartners Center for Memory & Aging. As of 1989 Frey had been “in the Alzheimer’s deal” for over a decade. At that time he was conducting clinical trials of a neurotrophic factor (a therapeutic protein) to treat AD and, because of the seeming insurmountability of the BBB, the work had been less than fruitful. “It became clear to me that, once again, this neurotrophic factor was not getting effectively into the brain,” he says. So Frey decided to sleep on it. “I went to sleep and I had a dream. And this is how I discovered the intranasal method of getting around the blood brain barrier,” he says. “It had been known since the early 1900s that a number of different viruses that got into the nose would travel up the olfactory nerves and the trigeminal nerves—both of these are nerves that go directly from the nasal mucosa right into the brain. The idea that came to me in this dream in 1989 was: if bad things can do it, why can’t good things do it?”
When Frey revisited the idea upon waking, it registered as simultaneously intuitive and absurd—a logical fantasy like so many dreams.
The Latest Bing News on:
- Does Intermittent Fasting Really Promote Weight Loss?on November 10, 2020 at 7:33 pm
Intermittent fasting has been touted high and low as the ideal anti-inflammatory diet; we even did a deep dive into the ins and outs of intermittent fasting (and busted a few intermittent fasting ...
- Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2020 Results - Earnings Call Transcripton November 9, 2020 at 12:49 am
AMPH) Q3 2020 Earnings Conference Call November 6, 2020 12:00 ET Company Participants Dan Dischner - Vice President of Human Resources & Corporate Communications Bill Peters - Chief Financial Officer ...
- Amphastar Pharmaceuticals' (AMPH) Management On Q3 2020 Results - Quick Version Earnings Call Transcripton November 6, 2020 at 4:05 pm
AMPH) Q3 2020 Earnings Conference Call November 6, 2020 11:50 AM ET Company Participants Dan Dischner - Vice President of Human Resources and Corporate Communications Bill Peters - Chief Financial ...
- Is Alzheimer’s Disease Really Type 3 Diabetes?on October 25, 2020 at 9:26 pm
Midway through the previous century, a relationship between diabetes and dementia was noticed. In 1995, an article in Medical Hypothesis posited that diabetes and Alzheimer’s disease (AD) may have a ...
- A dangerous new coronavirus complication was discovered – and it never goes away if you get iton October 21, 2020 at 10:29 am
Some patients will need expensive insulin therapy for the rest of their lives. Diabetes is one of the most serious risk factors for COVID-19 complications and death, and it turns out that there ...
- Insulin Pens Market Scope and Growing Demands 2020 : Key Players: Novo Nordisk, Sanofi, Smiths Medical Asd, Inc., Biocon, Health Care Center, Etc.on October 16, 2020 at 9:17 am
Radical Features of the Insulin Pens Market Report: 1. Intranasal Drug Delivery Devices Market Size, Share & Global Industry Demand, Outlook By Type, By Technology, By Product, By Application ...
- Revolutionary inventions from the year you were bornon October 14, 2020 at 8:37 am
Medical breakthroughs have given diabetics insulin, created the artificial heart, and made blood banks possible. The discovery of penicillin led to modern antibiotics, and vaccines have eradicated ...
- Early Intranasal Insulin Therapy Halts Progression of Neurodegenerationon October 12, 2020 at 5:00 pm
 The subjects were treated with either a placebo, or one of two doses (20–40 IU) of intranasal insulin. At the end of a 4-month protocol, memory and cognitive performance were assessed to ...
- Simple treatment that could free diabetics from insulinon October 12, 2020 at 3:37 pm
Trial of new procedure saw 75 per cent of diabetic patients stop using insulin New method sees a small balloon with hot water passed down patient's throat Around a quarter of Type 2 diabetics ...
- Intranasal Insulin Enhanced Resting-state Functional Connectivity of Hippocampal Regions in Type 2 Diabeteson September 23, 2020 at 4:59 pm
Type 2 diabetes mellitus (T2DM) alters brain function and manifests as brain atrophy. Intranasal insulin has emerged as a promising intervention for treatment of cognitive impairment. We evaluated ...
The Latest Google Headlines on:
The Latest Bing News on:
- Study shows how to detect Alzheimer’s disease before symptoms showon November 13, 2020 at 7:54 am
A researcher at the University of Missouri has recently completed research producing methods for defining the presymptomatic stages of Alzheimer’s disease.
- Link between Alzheimer's disease and gut microbiota is confirmedon November 13, 2020 at 7:34 am
Alzheimer's disease is the most common cause of dementia. Still incurable, it directly affects nearly one million people in Europe, and indirectly millions of family members as well as society as a ...
- In honor of Pat: Fulmer promotes 2020 fundraising goal to benefit Alzheimer's disease researchon November 13, 2020 at 6:24 am
University of Tennessee Athletics Director Phillip Fulmer doesn't want it to end there. Fulmer on Thursday called on East Tennesseans to continue donating through the rest of the year, particularly by ...
- 85-year-old man with Alzheimer’s missing in Garland found safeon November 13, 2020 at 5:55 am
Police are seeking the public’s help in locating an 85-year-old Garland man diagnosed with Alzheimer’s Disease who has been missing ...
- Traumatic Brain Injury Tied to Accelerated Alzheimer's Riskon November 12, 2020 at 1:27 pm
New research provides biological clues as to why sustaining a traumatic brain injury can increase and accelerate dementia risk.
- Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals?on November 12, 2020 at 12:18 pm
Biogen's Alzheimer's disease drug, aducanumab, got positive news from the FDA last week. If the drug is approved, what does that mean for other companies with prospective Alzheimer's drug candidates?
- Active For Life music programs helping Alzheimer’s and dementia patients dance and sing againon November 12, 2020 at 6:21 am
There’s a recent viral video of a famous New York City prima ballerina suffering from Alzheimer’s who upon listening to “Swan Lake” magnificently performs once again from her wheelchair.
- Dr. Oz will be guest speaker at Alzheimer’s Foundation of America virtual conferenceon November 12, 2020 at 6:14 am
Connecticut residents affected by Alzheimer's are invited to free virtual educational conference on Tuesday, Nov. 17 sponsored by the Alzheimer's Foundation of America.
- Alzheimer’s Patient Dancing to ‘Swan Lake’: Mystery Behind The Viral Videoon November 12, 2020 at 4:05 am
A video of Marta C. González, a Spanish dancer who battled Alzheimer’s disease, dancing while she is in a wheelchair has gone viral.
- AlzeCure receives approval to start clinical Phase I trial with ACD856 in Alzheimer's diseaseon November 12, 2020 at 3:43 am
PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of ...